Elliott L. Fineman
Director Ejecutivo en Planet Biotechnology, Inc. .
Perfil
Elliott L.
Fineman is the founder of SuperGen, Inc. founded in 1991.
He is currently the President & Chief Executive Officer at Planet Biotechnology, Inc. since 1998.
He previously worked as the Chief Operating Officer at SuperGen, Inc. and as a Principal at Cetus Corp.
Mr. Fineman has an undergraduate degree from Oberlin College, a graduate degree from the University of Baltimore, and another graduate degree from Georgetown University.
Cargos activos de Elliott L. Fineman
| Empresas | Cargo | Inicio |
|---|---|---|
Planet Biotechnology, Inc.
 Planet Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Planet Biotechnology, Inc. identifies and develops promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. The company was is headquartered in Hayward, CA. | Director Ejecutivo | 01/01/1998 |
Antiguos cargos conocidos de Elliott L. Fineman.
| Empresas | Cargo | Fin |
|---|---|---|
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Fundador | 13/09/2011 |
| Cetus Corp. | Corporate Officer/Principal | - |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Director de Operaciones | - |
Formación de Elliott L. Fineman.
| University of Baltimore | Graduate Degree |
| Georgetown University | Graduate Degree |
| Oberlin College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
Planet Biotechnology, Inc.
Planet Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Planet Biotechnology, Inc. identifies and develops promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. The company was is headquartered in Hayward, CA. | Health Technology |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
| Cetus Corp. | Health Technology |
- Bolsa de valores
- Insiders
- Elliott L. Fineman
